Abstract: A connector (F) includes an inner housing (11) configured to accommodate terminal fittings (72). An outer housing (37) is separate from the inner housing (11) and is configured to surround the inner housing (11). A lock arm (17) is formed on an outer surface of the inner housing (11) and is configured to lock the inner housing (11) and a mating housing (80) in a connected state by being locked to the mating housing (80). Protecting portions (45, 46) are formed on the outer housing (37) and are arranged near a lock releasing portion (22) of the lock arm (17).

Abstract: A moving plate (30) includes two resilient locking pieces (34) and can be resiliently curved and deformed to incline a projecting direction of the resilient locking pieces (34), and a female housing (50) pulls the moving plate 30 back to an initial position by locking locks (55) to the resilient locking pieces (34). With the moving plate (30) held at the initial position by initial position holding projections (18), the locks (55) of the female housing (50) are displaced to locked positions to the resilient locking pieces (34) by resiliently deforming the resilient locking pieces (34). The initial position holding projections (18) are spaced apart in the same direction as a separating direction of the resilient locking pieces (34) and arranged at positions different from the pair of resilient locking pieces (34) in the separating direction of the pair of resilient locking pieces (34).

Abstract: A moving plate (30) includes two resilient locking pieces (34) and can be resiliently curved and deformed to incline a projecting direction of the resilient locking pieces (34). With the moving plate (30) held at an initial position by retaining projections (21), locks (55) of a female housing (50) are displaced from positions where the locks (55) are locked to the resilient locking pieces (34) to positions where the locks (55) are not locked to the resilient locking pieces (34) by resiliently deforming the resilient locking pieces (34). The retaining projections (21) are spaced apart in the same direction as a separating direction of the resilient locking pieces (34) and are at positions different from the resilient locking pieces (34) in the separating direction of the resilient locking pieces (34).

Abstract: A male housing of a connector assembly has moving plate (30) with a pair of resilient locking pieces (34) that can be curved resiliently and deformed to incline a projecting direction of the resilient locking pieces (34). A female housing (50) causes the moving plate (30) to interfere with initial position holding projections (18) and pulls the moving plate (30) back to an initial position by locking with locking portions (55) to the resilient locking pieces (34). The initial position holding projections (18) are paired and spaced apart in the same direction as a separating direction of the resilient locking pieces (34) and are arranged at positions different from the resilient locking pieces (34) in the separating direction of the resilient locking pieces (34).

Abstract: Locking lances (12) for retaining and locking terminal fittings (60) are deflectably provided at inner walls of cavities (11) of a housing (10). The housing (10) includes excessive deflection regulating pieces (13) each provided at a position facing the locking lance (12) in a deflecting direction of the locking lance (12) and configured to regulate excessive deflection of the locking lance (12). Locking lances (12) are provided side by side in a width direction perpendicular to an inserting direction of the terminal fittings (60). A plurality of the excessive deflection regulating pieces (13) are provided side by side in the width direction at positions corresponding to the locking lances (12) and have also a function of positioning an inspection tool (70) for inspecting an inserted state of the terminal fittings (60).

Abstract: Locking lances (12) for retaining and locking terminal fittings (60) are deflectably provided at inner walls of cavities (11) of a housing (10). The housing (10) includes excessive deflection regulating pieces (13) each provided at a position facing the locking lance (12) in a deflecting direction of the locking lance (12) and configured to regulate excessive deflection of the locking lance (12). Locking lances (12) are provided side by side in a width direction perpendicular to an inserting direction of the terminal fittings (60). A plurality of the excessive deflection regulating pieces (13) are provided side by side in the width direction at positions corresponding to the locking lances (12) and have also a function of positioning an inspection tool (70) for inspecting an inserted state of the terminal fittings (60).

Abstract: A connector includes a one-piece rubber plug (30) arranged to cover a rear surface (10R) of an inner housing (10) and has seal holes (31) aligned with cavities 12. An outer housing (20) has a tubular portion (21) surrounding the inner housing (10) and a rear wall (24) covering a rear surface (30R) of the one-piece rubber plug (30). The rear wall (24) has insertion holes (25) aligned with the seal holes (31). Locking holes (26A, 26B) are open on a rear surface (24R) of the rear wall (24), and locks (17A, 17B) on the inner housing (10) engage with the locking holes (26A, 26B) to lock the housings (10, 20) in an assembled state.

Abstract: The present invention relates to macrocyclic small molecule inhibitors of the Sonic Hedgehog signaling pathway, syntheses thereof, and intermediates thereto. Such small molecule modulators of the Sonic Hedgehog signaling pathway are useful in the treatment of proliferative diseases (e.g., basal cell carcinoma, Gorlin syndrome, medulloblastoma, or pancreatic cancer), pulmonary diseases (e.g., interstitial pnuemonitis or interstitial pulmonary fibrosis), and developmental disorders (e.g., phocomelia or cyclopia). Novel non-natural macrocycles are provided that inhibit Sonic Hedgehog induced-protein transcription.

Abstract: A connector includes a one-piece rubber plug (30) arranged to cover a rear surface (10R) of an inner housing (10) and has seal holes (31) aligned with cavities 12. An outer housing (20) has a tubular portion (21) surrounding the inner housing (10) and a rear wall (24) covering a rear surface (30R) of the one-piece rubber plug (30). The rear wall (24) has insertion holes (25) aligned with the seal holes (31). Locking holes (26A, 26B) are open on a rear surface (24R) of the rear wall (24), and locks (17A, 17B) on the inner housing (10) engage with the locking holes (26A, 26B) to lock the housings (10, 20) in an assembled state.

Abstract: The present invention relates to relates to macrocyclic small molecule inhibitors of the Sonic Hedgehog signaling pathway, syntheses thereof, and intermediates thereto. Such small molecule modulators of the Sonic Hedgehog signaling pathway are useful in the treatment of proliferative diseases (e.g., basal cell carcinoma, Gorlin syndrome, medulloblastoma, or pancreatic cancer), pulmonary diseases (e.g., interstitial pnuemonitis or interstitial pulmonary fibrosis), and developmental disorders (e.g., phocomelia or cyclopia). Novel non-natural macrocycles are provided that inhibit Sonic Hedgehog induced-protein transcription.

Abstract: The present invention provides a compound having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases. As a result of studies on a novel condensed heterocyclic derivative, the inventors have found that a compound having a cross-linked structure has an excellent JAK3 inhibition activity, and have completed the present invention. In other words, it is verified that the compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g.

Abstract: The present invention provides a compound of formula (I) having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases inflammatory diseases, and allergic diseases. The compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ/tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia).

Abstract: There is provided fused heterocycles of imidazopyridazine or pyrazolopyrimidine derivative represented by the formula (I), which have excellent Lck inhibitory activity and are useful for a medicament particularly an immunosuppressive agent. [wherein one of Y and Z is C atom, and the other is N atom; —X— is —N(R1)— or the like, —R1 represents hydrogen or the like, -A- represents bond or the like, —R2 is cycloalkyl, aryl or the like, -E- is bond or the like, —R3 is aryl, aromatic heterocycle or the like, —R4, —R5 and —R6 are the same or different, each being hydrogen or the like.

Abstract: The present invention provides a compound of formula (I) having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases inflammatory diseases, and allergic diseases. The compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ/tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia).

Abstract: This invention relates to piperazine derivatives of the formula: wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human being or animals.

Abstract: This invention relates to piperazine derivatives of the formula: wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human being or animals.

Abstract: This invention relates to piperazine derivatives of the formula: wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human being or animals.

Abstract: This invention relates to piperazine derivatives of the formula: wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human being or animals.

Abstract: This invention relates to piperazine derivatives of the formula: wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human being or animals.

Abstract: A compound of the formula (I): wherein in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are each as defined in the description, or a salt thereof. The object compound of the present invention has pharmacological activities such as Tachykinin antagonism and is useful for manufacture of a medicament for treating or preventing Tachykinin-mediated diseases.